Analysts Set Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) PT at $6.75

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) have been assigned a consensus recommendation of “Hold” from the nine ratings firms that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and four have given a buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $6.75.

Several research analysts have commented on ZNTL shares. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Zentalis Pharmaceuticals in a research note on Friday, May 22nd. Rodman & Renshaw initiated coverage on shares of Zentalis Pharmaceuticals in a research note on Thursday, July 23rd. They issued a “buy” rating and a $11.00 price objective for the company. Wall Street Zen cut shares of Zentalis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a report on Monday, July 6th. Finally, Mizuho assumed coverage on shares of Zentalis Pharmaceuticals in a research report on Friday, July 17th. They issued an “outperform” rating and a $8.00 target price on the stock.

Zentalis Pharmaceuticals Trading Down 2.2%

Shares of Zentalis Pharmaceuticals stock opened at $3.51 on Thursday. The firm has a market capitalization of $251.56 million, a PE ratio of -1.80 and a beta of 1.85. The business’s 50-day moving average price is $4.30 and its 200-day moving average price is $3.82. Zentalis Pharmaceuticals has a 12 month low of $1.21 and a 12 month high of $6.95.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.10). As a group, analysts predict that Zentalis Pharmaceuticals will post -2.14 earnings per share for the current fiscal year.

Insider Transactions at Zentalis Pharmaceuticals

In related news, major shareholder Group Walters acquired 4,335,000 shares of Zentalis Pharmaceuticals stock in a transaction dated Friday, August 14th. The shares were purchased at an average cost of $3.50 per share, with a total value of $15,172,500.00. Following the completion of the purchase, the insider owned 17,844,973 shares of the company’s stock, valued at $62,457,405.50. This represents a 32.09% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 3.80% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. GSA Capital Partners LLP purchased a new stake in Zentalis Pharmaceuticals during the 2nd quarter valued at $1,815,000. Seven Fleet Capital Management LP increased its position in shares of Zentalis Pharmaceuticals by 188.7% in the second quarter. Seven Fleet Capital Management LP now owns 317,600 shares of the company’s stock valued at $1,451,000 after acquiring an additional 207,600 shares during the period. BlackRock Inc. purchased a new position in shares of Zentalis Pharmaceuticals in the second quarter valued at about $18,205,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Zentalis Pharmaceuticals during the second quarter valued at about $3,676,000. Finally, Primecap Management Co. CA bought a new position in shares of Zentalis Pharmaceuticals during the second quarter valued at about $4,643,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.